The Pfizer/BioNTech bivalent COVID-19 vaccine (Original and Omicron BA.4/BA.5) has the FDA’s EUA for use in individuals 5 years and over as a single booster dose administered at least two months ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

Abrysvo is the first vaccine for the respiratory syncytial virus that is indicated for adults younger than 50, the drugmaker ...

There is no evidence Japan has named the COVID-19 vaccine the “most deadly drug in history,” as the post claims.

Pfizer's Abrysvo is FDA-approved to prevent RSV in adults 18-59 at high risk. Abrysvo remains the only RSV vaccine approved for pregnant individuals to protect infants. Abrysvo now offers the ...

Oct 22 (Reuters) - The U.S. Food and Drug Administration on Tuesday approved Pfizer's (PFE.N), opens new tab RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in ...

The US Food and Drug Administration (FDA) has expanded the indication for Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo to include adults aged 18–59 years who have chronic ...

New guidelines and the timing of COVID vaccinations impacted uptake of Abrysvo this year, according to a company executive.

Earlier in October, Pfizer Inc (NYSE: PFE ... budget by $1.1 billion over the next three years while it aims to get FDA ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant.

The Food and Drug Administration expanded its approval of Pfizer’s vaccine for a deadly respiratory virus to a new age group. The vaccine, called Abrysvo, has been approved for the prevention of ...